International Biotechnology (LON:IBT) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell?

Key Points

• International Biotechnology's stock price recently crossed above its 200-day moving average at GBX 624.28, peaking at GBX 658 during trading.
• The company reported a net margin of 90.66% and a return on equity of 13.67%, with expected earnings per share of 0.94 this year.
• Insider Katherine Cornish-Bowden bought 2,000 shares at GBX 585, indicating confidence in the company's future performance.

International Biotechnology (LON:IBT - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 624.28 ($8.30) and traded as high as GBX 658 ($8.75). International Biotechnology shares last traded at GBX 656 ($8.72), with a volume of 426,698 shares trading hands.

International Biotechnology Stock Performance

The firm has a market capitalization of £235.04 million, a PE ratio of 6.24 and a beta of 0.21. The company's fifty day moving average price is GBX 612.49 and its two-hundred day moving average price is GBX 624.28.

International Biotechnology (LON:IBT - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported GBX (5.60) (($0.07)) earnings per share for the quarter. International Biotechnology had a return on equity of 13.67% and a net margin of 90.66%. On average, equities analysts expect that International Biotechnology will post 0.9435943 earnings per share for the current year.

Insider Buying and Selling at International Biotechnology

In related news, insider Katherine Cornish-Bowden acquired 2,000 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were acquired at an average cost of GBX 585 ($7.78) per share, for a total transaction of £11,700 ($15,556.44). 4.18% of the stock is currently owned by insiders.

International Biotechnology Company Profile

The Company's investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies. The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.